Zai Lab Announces China’s NMPA Grants Priority Review to the sNDA for ZEJULA (Niraparib) for First-Line Ovarian Cancer Maintenance Treatment

Zai Lab Announces China’s NMPA Grants Priority Review to the sNDA for ZEJULA (Niraparib) for First-Line Ovarian Cancer Maintenance Treatment

Ads